In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program.
BATON ROUGE, La., Aug. 23, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB:GBLX) With the first cannabis crop now in production at their high-tech 36,000 square-foot grow facility in Baton Rouge, teams from GB Sciences and the LSU AgCenter are working closely with Louisiana pharmacists who will serve patients starting in November.
Some three years after the passage of the Alison Neustrom Act, the Louisiana Pharmacy Board has issued permits to nine pharmacists who will dispense medical marijuana in their nine respective regions of the state (see box below), with a potential 10th license to be awarded at a later date in a high-demand area.
Louisiana Pharmacies by Region
Region 1 — Metropolitan - H & W Drug Store, New Orleans
Region 6 — Central - The Medicine Cabinet Pharmacy – Alexandria
Region 7 — Northwest - Hope Pharmacy – Shreveport
Region 8 — Northeast - Delta Medmar - West Monroe
Region 9 — Southeast - Willow Pharmacy - Madisonville
Patients must have a prescription from a physician for a qualifying medical condition (see box below). Pharmacists will dispense formulations in the form of pills, oils, and topical solutions. None of the cannabis formulation may be smoked.
Qualifying Disease States
• Cachexia or wasting syndrome
• Seizure disorders
• Crohn's disease
• Muscular dystrophy
• Multiple sclerosis
• Parkinson's disease
• Severe muscle spasms
• Intractable pain
• Autism spectrum disorder
On August 9th, representatives from the nine pharmacies toured the high-tech GB Sciences facility in Baton Rouge, LA.
"We looked at the grow rooms, processing, spoke with a number of the executives there, all very knowledgeable … a state-of-the-art facility," said John Condos, a Louisiana business owner. "Security was unbelievable, all of which shows me that GB Sciences is committed to making this process in Louisiana a success."
"I'm just excited to be able to offer a new opportunity to patients," said Randy Mire, a pharmacist who will serve patients in and around Baton Rouge. "This is a much-needed medication that I think many people can benefit from and to be able to offer that in Louisiana is just something I'm so proud of."
"We are on the front edge of this wave of research into the cannabis plant," said John Davis, President of GB Sciences Louisiana. "And vital to that is our strategic partnership with the nine pharmacies that have been licensed by the Louisiana Board of Pharmacy."
"We're very excited that they are as far along as they are," said Hampton Grunewald, Associate Vice President of Governmental Relations at the LSU AgCenter. "They've been working to develop not only the protocols that they'll be following, but the procedures for dispensing products to patients."
About Louisiana State University Agricultural Center
The Louisiana State University Agricultural Center ("LSU AgCenter" or "AgCenter") is an institution under the supervision and management of the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (the "LSU Board of Supervisors"). The AgCenter's mission is to provide the people of Louisiana with research-based educational information that will improve their lives and economic well-being. The LSU AgCenter includes the Louisiana Agricultural Experiment Station, which conducts Agricultural and Renewable Natural Resource-based research, and the Louisiana Cooperative Extension Service, which extends the knowledge derived from research to the people of the state. The LSU AgCenter plays an integral role in supporting agricultural industries, enhancing the environment, and improving the quality of life through its 4-H youth, family and consumer sciences, and community development programs.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118 866-721-0297, or Tom Arcuragi, EVP, [email protected]